

Edgar Filing: SANOFI-AVENTIS - Form 6-K

SANOFI-AVENTIS  
Form 6-K  
November 05, 2004

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

-----  
FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a-16 OR 15d-16  
UNDER THE SECURITIES EXCHANGE ACT OF 1934

-----  
For the month of November 2004

Commission File Number: 001-31368

SANOFI-AVENTIS  
(Translation of registrant's name into English)

174, avenue de France, 75013 Paris, FRANCE  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F  [X]

Form 40-F  [ ]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b) (1): \_\_\_\_\_

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b) (7): \_\_\_\_\_

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  [ ]

No  [X]

If "Yes" marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-\_\_\_\_\_

On November 4, Sanofi-Aventis (formerly known as Sanofi-Synthelabo) issued the press release attached hereto as Exhibit 99.1, announcing European Union approval for Taxotere(R) (docetaxel) in the treatment of prostate cancer. Exhibit 99.1 is incorporated herein by reference.

On November 5, Sanofi-Aventis issued the press release attached hereto as Exhibit 99.2, announcing United States Food and Drug Administration approval for Eloxatin(R) (oxaliplatin for injection) in the adjuvant (postsurgical) treatment of colon cancer. Exhibit 99.2 is incorporated herein by reference.

EXHIBIT LIST

EXHIBIT NO.

DESCRIPTION

## Edgar Filing: SANOFI-AVENTIS - Form 6-K

- Exhibit 99.1 Press Release, dated November 4, 2004, issued by Sanofi-Aventis announcing European Union approval for Taxotere(R) (docetaxel) in the treatment of prostate cancer.
- Exhibit 99.2 Press Release, dated November 5, 2004, issued by Sanofi-Aventis announcing United States Food and Drug Administration approval for Eloxatin(R) (oxaliplatin for injection) in the adjuvant (postsurgical) treatment of colon cancer.

### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: November 5, 2004

SANOFI-AVENTIS

By: /s/ Jean-Claude Leroy

-----  
Name: Jean-Claude Leroy  
Title: Senior Vice President &  
Chief Financial Officer

### EXHIBIT INDEX

- | EXHIBIT NO.  | DESCRIPTION  |
|--------------|--|
| Exhibit 99.1 | Press Release, dated November 4, 2004, issued by Sanofi-Aventis announcing European Union approval for Taxotere(R) (docetaxel) in the treatment of prostate cancer.  |
| Exhibit 99.2 | Press Release, dated November 5, 2004, issued by Sanofi-Aventis announcing United States Food and Drug Administration approval for Eloxatin(R) (oxaliplatin for injection) in the adjuvant (postsurgical) treatment of colon cancer. |